Cargando…
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Rat sarcoma (RAS), as a frequently mutated oncogene, has been studied as an attractive target for treating RAS‐driven cancers for over four decades. However, it is until the recent success of kirsten‐RAS (KRAS)(G12C) inhibitor that RAS gets rid of the title “undruggable”. It is worth noting that the...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225044/ https://www.ncbi.nlm.nih.gov/pubmed/37250144 http://dx.doi.org/10.1002/mco2.285 |